View Older Stories View More Recent Stories

May 4, 2026 08:01AM Clene plans accelerated FDA filing for ALS drug CNM-Au8 in Q3 2026
May 4, 2026 08:00AM After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS
Mar 12, 2026 08:00AM Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights
Feb 24, 2026 08:00AM Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts
Feb 24, 2026 07:00AM Presenting on Emerging Growth Conference 90 Day 1 on February 25; Register to live stream
Feb 19, 2026 08:30AM Clene to Present at the Emerging Growth Conference
Jan 20, 2026 07:00AM Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live stream
Jan 16, 2026 08:30AM Clene to Present at the Emerging Growth Conference
Jan 12, 2026 08:31AM Clene secures FDA meeting to discuss ALS drug biomarker data
Jan 12, 2026 08:30AM Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting
Jan 9, 2026 08:30AM Clene raises over $28 million in registered direct offering
Jan 9, 2026 08:30AM Clene Announces Registered Direct Offering of Over $28 Million
Dec 9, 2025 08:30AM Clene to Present at the Emerging Growth Conference
Dec 9, 2025 07:00AM Presenting on Emerging Growth Conference 88 Day 1 on December 10; Register to live stream
Dec 3, 2025 08:01AM Clene reports positive ALS biomarker data for CNM-Au8 drug candidate
Dec 3, 2025 08:00AM Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®
Dec 2, 2025 05:39PM Clene to Provide CNM-Au8® ALS Program Update
Nov 20, 2025 08:00AM Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference
Nov 13, 2025 08:00AM Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights
Oct 22, 2025 07:00AM Presenting on Emerging Growth Conference 87 Day 2 on October 23; Register to live stream
Oct 20, 2025 08:30AM Clene to Present at the Emerging Growth Conference
Oct 15, 2025 08:30AM Clene to Participate in a Panel Discussion at the Maxim Growth Summit
Sep 25, 2025 08:00AM Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients
Sep 4, 2025 08:30AM Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson’s Disease
Sep 2, 2025 08:00AM Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Aug 19, 2025 07:00AM Presenting on Emerging Growth Conference 85 Day 1 on August 20; Register to live stream
Aug 14, 2025 08:38AM Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights
Aug 13, 2025 08:00AM Clene to Present at the Emerging Growth Conference
Aug 5, 2025 08:30AM Clene to Present at the Canaccord 45th Annual Growth Conference
Jul 16, 2025 07:00AM Presenting on Emerging Growth Conference 84 Day 2 on July 17; Register to live stream
Jun 30, 2025 08:05AM Clene (CLNN) Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings
Jun 30, 2025 08:00AM Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings
Jun 9, 2025 09:00AM Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025
May 20, 2025 07:00AM Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream
May 7, 2025 08:00AM Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights
May 7, 2025 08:00AM Clene Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference
Apr 16, 2025 07:00AM Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream
Apr 14, 2025 08:30AM Clene to Present at the Emerging Growth Conference
Apr 8, 2025 08:07AM Clene (CLNN) Presents Evidence of Remyelination and Neuronal Repair With CNM-Au8® Treatment At the American Academy of Neurology Late-Breaking Science Session
Apr 8, 2025 08:00AM Clene Presents Evidence of Remyelination and Neuronal Repair With CNM-Au8® Treatment At the American Academy of Neurology Late-Breaking Science Session
Apr 1, 2025 08:30AM Clene to Present at the Jones Healthcare and Technology Innovation Conference
Mar 24, 2025 08:00AM Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights
Mar 12, 2025 08:02AM Clene (CLNN) Demonstrates Strengthened ALS Survival Benefit with CNM-Au8 Treatment
Mar 12, 2025 08:00AM Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment
Mar 6, 2025 08:30AM Clene to Present at the 37TH Annual Roth Conference
Feb 25, 2025 08:03AM Clene (CLNN) and APST Enter Into an Agreement to Support FDA’s Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®’s Impact on NfL Reduction
Feb 25, 2025 08:00AM Clene and APST Enter Into an Agreement to Support FDA’s Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®’s Impact on NfL Reduction
Dec 19, 2024 08:00AM Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan
Dec 10, 2024 08:30AM FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS
Nov 13, 2024 08:00AM Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights
View More Recent Stories View Older Stories